Relmada Therapeutics Inc (RLMD) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The Phase 3 study titled “A Phase 3 Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy” aimed to test a new bladder cancer treatment in patients with limited options. It focused on people whose cancer did not respond to standard BCG care and who were already being advised to have bladder removal surgery.
The trial planned to use NDV-01, a drug that combines gemcitabine and docetaxel in a slow-release form. It is given directly into the bladder through a catheter and is meant to control tumors while delaying or avoiding major surgery.
The design was interventional and single arm, meaning every participant would receive NDV-01 and there was no comparison group. The study was open label with no blinding, and the main purpose was treatment, with safety and tumor response as key measures for future approval talks.
The study was first submitted in January 2026, marking the sponsor’s formal move to late-stage testing. A major update was filed in March 2026, but the status now shows “withdrawn,” suggesting the trial did not move ahead as planned and timelines for primary and final completion are no longer applicable.
For investors, the withdrawal of this Phase 3 study removes a potential near-term value driver for Relmada Therapeutics, Inc. (RLMD). It may weigh on sentiment, as late-stage oncology assets can support premium valuations, while competitors in bladder cancer, including larger oncology players, now face less direct pressure from this specific program.
The change in status may prompt questions about capital allocation, pipeline focus, and regulatory strategy at RLMD, and could increase stock volatility in the short term. While the company may redirect resources toward other assets, investors will likely wait for clearer guidance before re-rating the stock, and the withdrawn bladder cancer study remains documented and updated on the ClinicalTrials portal.
To learn more about RLMD’s potential, visit the Relmada Therapeutics Inc drug pipeline page.